

# Our Global Statement on Patents & Intellectual Property

## BeOne's Position

Intellectual property (IP) protection is essential to BeOne's ability to research and develop new and innovative medicines. Biopharmaceutical research and development (R&D) is a long, expensive, and high-risk venture, typically taking 10–15 years and costing around \$2 billion per medicine with a high risk of failure. Patents provide a critical incentive to the private sector to undertake the substantial financial and developmental risk associated with pharmaceutical innovations. Without IP protection companies would struggle to sustain the R&D process. At BeOne, we are committed to responsible IP usage, as we believe it is the key to driving both therapeutic innovation and access to treatment for all patients.

BeOne recognizes that the cost of innovative medicines—particularly specialized treatments like those for cancer—is a key concern for patients, healthcare providers, and governments. As part of our commitment to balancing innovation with affordability, BeOne participates in initiatives aimed at increasing treatment access in underserved regions. This includes our role as a founding member of the Union for International Cancer Control's Access to Oncology Medicines (ATOM) Coalition. The ATOM Coalition works alongside local governments and stakeholders in select low and lower middle-income countries to address oncology needs by facilitating voluntary licensing, partnering with manufacturers, and ensuring quality-assured cancer medicines are available at sustainable prices.

By pursuing both strong IP protection and strategic access initiatives, BeOne remains committed to developing breakthrough therapies while ensuring they reach the patients who need them most.